Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin

The positive findings of the EMPA-REG OUTCOME trial (Randomized, Placebo-Controlled Cardiovascular Outcome Trial of Empagliflozin) on heart failure (HF) outcome in patients with type 2 diabetes mellitus suggest a direct effect of empagliflozin on the heart. These patients frequently have HF with pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Juni, Rio P., Kuster, Diederik W.D., Goebel, Max, Helmes, Michiel, Musters, René J.P., van der Velden, Jolanda, Koolwijk, Pieter, Paulus, Walter J., van Hinsbergh, Victor W.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
PRECLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872802/
https://www.ncbi.nlm.nih.gov/pubmed/31768475
http://dx.doi.org/10.1016/j.jacbts.2019.04.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872802/
https://www.ncbi.nlm.nih.gov/pubmed/31768475
http://dx.doi.org/10.1016/j.jacbts.2019.04.003

Ejemplares similares